Indometacin transdermal - Andromaco/UMeWorld

Drug Profile

Indometacin transdermal - Andromaco/UMeWorld

Alternative Names: Indaflex; Indometacin transdermal - AlphaRx/Cypress; Indomethacin transdermal - AlphaRx; PRO-406

Latest Information Update: 05 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AlphaRx
  • Developer Andromaco; UMeWorld
  • Class Analgesics; Antirheumatics; Chlorobenzenes; Indoles; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Osteoarthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 15 Apr 2013 AlphaRx is now called UMeWorld
  • 22 Feb 2013 Indometacin transdermal is available for licensing worldwide (excluding Mexico) as of 22 Feb 2013. http://www.umeworld.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top